(Q40859532)

24 September 2017

title

Six decades of vaccine development--a personal history (English)

1 reference

24 September 2017

1

M R Hilleman

1 reference

24 September 2017

language of work or name

English

0 references

publication date

1 May 1998

1 reference

24 September 2017

1 reference

24 September 2017

volume

4

1 reference

24 September 2017

issue

5 Suppl

1 reference

24 September 2017

page(s)

507-514

1 reference

https://scigraph.springernature.com/pub.10.1038/nm0598supp-507

24 September 2017

exact match

0 references

cites work

Preparation of dried antigen and antiserum for the agglutination-inhibition test for virus influenza

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

Laboratory studies on the 1950 outbreak of influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

Antibody response in volunteers to Asian influenza vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

Development of a purified poliomyelitis virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

The vacuolating virus, S.V. 40

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

Safety and Immunogenicity of a Live Attenuated Hepatitis A Virus Vaccine in Seronegative Volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

Acute respiratory illnesses among children and adults. Field study of contemporary importance of several viruses and appraisal of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

Live respiratory syncytial virus vaccine administered parenterally

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

Cultivation of the Lansing Strain of Poliomyelitis Virus in Cultures of Various Human Embryonic Tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Pneumococcus: the first one hundred years.

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Antigenic variation of influenza viruses

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

New antigenic variant in Far East influenza epidemic, 1957.

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Status report on adenoviruses and Asian influenza.

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Recovery of new agent from patients with acute respiratory illness

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Epidemiologic investigations with respiratory disease virus RI-67.

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Clinical and laboratory studies in patients with respiratory disease caused by adenoviruses (RI-APC-ARD agents)

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Biophysical characterization of the RI (RI-67) viruses

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Electron microscopy of type 4 adenovirus strain R1-67

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Grouping and occurrence of RI (prototype RI-67) viruses

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Adenoviruses: group name proposed for new respiratory-tract viruses

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Prevention of acute respiratory illness in recruits by adenovirus (RI-APC-ARD) vaccine

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Adenovirus (RI-APC-ARD) vaccine for prevention of acute respiratory illness. I. Vaccine development

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Second field evaluation of bivalent Types 4 and 7 adenovirus vaccine

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Studies on an attenuated measles-virus vaccine. I. Development and preparations of the vaccine: technics for assay of effects of vaccination

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Studies on an attenuated measles-virus vaccine. II. Clinical, virologic and immunologic effects of vaccine in institutionalized children

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Living attenuated measles-virus vaccine in early infancy. Studies of the role of passive antibody in immunization

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Studies of live attenuated measles virus vaccine in man. I. Clinical aspects

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Studies of live attenuated measles virus vaccine in man. II. Appraisal of efficacy

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Development and Evaluation of the Moraten Measles Virus Vaccine

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Live attenuated mumps-virus vaccine. 3. Clinical and serologic aspects in a field evaluation

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Live attenuated mumps-virus vaccine. IV. Protective efficacy as measured in a field evaluation

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Recovery of rubella virus from army recruits.

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Live attenuated rubella virus vaccines prepared in duck embryo cell culture. II. Clinical tests in families and in an institution

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Live attenuated rubella virus vaccines prepared in duck embryo cell culture. I. Development and clinical testing

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Live, attenuated rubella-virus vaccine

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Live rubella vaccines in adults and children. HPV-77 and Merck-Benoit strains

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Standardization and mass application of combined live measles-smallpox vaccine in Upper Volta

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Clinical and Laboratory Studies of KMcC Strain Live Attenuated Varicella Virus

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Live attenuated varicella virus vaccine. Efficacy trial in healthy children

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Protection against Marek's Disease by Vaccination with a Herpesvirus of Turkeys

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Marek's disease vaccine: its implications in biology and medicine

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Development of tumors in hamsters inoculated in the neonatal period with vacuolating virus, SV-40.

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Factors influencing tumor induction in hamsters by vacuolating virus, SV.

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

INTERRUPTION OF SV-40 VIRUS TUMORIGENESIS USING IRRADIATED HOMOLOGOUS TUMOR ANTIGEN.

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

The origins of the small DNA tumor viruses

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Purified and inactivated human hepatitis B vaccine: progress report

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Vaccine against human hepatitis B

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Synthesis and assembly of hepatitis B virus surface antigen particles in yeast

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Human hepatitis B vaccine from recombinant yeast

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Yeast recombinant hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Production of purified hepatitis B surface antigen from Alexander hepatoma cells grown in artificial capillary units

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Vaccine against human hepatitis B virus prepared from antigen derived from human hepatoma cells in culture.

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

History, precedent, and progress in the development of mammalian cell culture systems for preparing vaccines: safety considerations revisited

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Recovery of Hepatitis Agents in the Marmoset from Human Cases Occurring in Costa Rica

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Etiologic relationship of marmoset-propagated CR326 hepatitis A virus to hepatitis in man.

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Studies on the transmission of human viral hepatitis to marmoset monkeys. I. Transmission of disease, serial passages, and description of liver lesions

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Identification of two flavivirus-like genomes in the GB hepatitis agent

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Biophysical and biochemical properties of CR326 human hepatitis A virus

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

An Inactivated Hepatitis A Virus Vaccine Prepared from Infected Marmoset Liver

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Progress toward a live, attenuated human hepatitis A vaccine

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

New findings in live, attenuated hepatitis A vaccine development

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

An inactivated hepatitis A viral vaccine of cell culture origin

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Hepatitis and hepatitis A vaccine: a glimpse of history

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Protective Efficacy of Pneumococcal Polysaccharide Vaccines

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Streptococcus pneumoniae polysaccharide vaccine: age and dose responses, safety, persistence of antibody, revaccination, and simultaneous administration of pneumococcal and influenza vaccines.

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Haemophilus influenzae type b polysaccharide-protein conjugate vaccine.

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Some further virus isolations from common colds.

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Recovery of new viruses (coryzavirus) from cases of common cold in human adults.

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Characterization and classification of ECHO 28-rhinovirus-coryzavirus agents

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

ADDITIONAL RHINOVIRUS SEROTYPES

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Rhinovirus infection in nursery and kindergarten children. New rhinovirus serotype 54

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Rhinoviruses: a description

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

EPIDEMIOLOGIC INVESTIGATIONS OF RHINOVIRUS INFECTIONS

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Attempt at immunization by oral feeding of live rhinoviruses in enteric-coated capsules

1 reference

https://api.crossref.org/works/10.1038%2FNM0598SUPP-507

7 January 2021

Identifiers

DOI

10.1038/NM0598SUPP-507

1 reference

Dimensions Publication ID

24 September 2017

1027327377

0 references

1 reference